who we are

Angion is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases.

The Angion team is dedicated to bring new therapeutic options to patients. Our initial focus is acute kidney injury and acute lung injury, where there are currently no pharmacologic therapies available, and chronic fibrotic conditions in the lung and kidney where effective treatments with more limited off-target toxicities are needed.

ANG-3777 clinical trials

If you wish to learn more about enrolling in our Phase 3 trial studying the safety and efficacy of ANG-3777 in patients with acute kidney injury related to kidney transplantation, click here.

If you wish to learn more about enrolling in the Phase 2 trial studying the safety and efficacy of ANG-3777 in patients with acute lung injury associated with COVID-19 related pneumonia, click here.

If you wish to learn more about enrolling in the Phase 2 trial studying the safety and efficacy of ANG-3777 in patients with acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass, click here.

OUR LEAD CLINICAL ASSET

ANG-3777

is engineered to activate the HGF/c-MET pathway,
an important mechanism in organ repair.

THE SCIENCE BEHIND

ANG-3777

ANG-3777 is a small molecule designed to mimic the biological activity of HGF, thereby activating the c-Met cascade of pathways involved in tissue repair and organ recovery. ANG-3777 has demonstrated several similarities to HGF, including c-Met dependence and selective c-Met receptor activation, without acting on other growth factor receptors. In addition, it has a substantially longer half-life than HGF. *

*ANG-3777 is currently being studied in clinical trials to determine if it is safe and effective. It is not yet approved for use by any regulatory agency globally.